NEXENTIS TECHNOLOGIES INC. Increase (Decrease) in Other Current Assets
NEXENTIS TECHNOLOGIES INC. (NXTS) reported Increase (Decrease) in Other Current Assets of -$164.88 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-04-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherCurrentAssets · last filed 2024-04-01
- NEXENTIS TECHNOLOGIES INC. increase (decrease) in other current assets for the quarter ending 2023-12-31 was -$41.94K.
- NEXENTIS TECHNOLOGIES INC. increase (decrease) in other current assets for the quarter ending 2023-09-30 was -$61.21K, a 286.20% decline year-over-year.
- NEXENTIS TECHNOLOGIES INC. increase (decrease) in other current assets for the quarter ending 2023-06-30 was -$77.70K, a 130.29% decline year-over-year.
- NEXENTIS TECHNOLOGIES INC. increase (decrease) in other current assets for the quarter ending 2023-03-31 was $15.98K.
- NEXENTIS TECHNOLOGIES INC. increase (decrease) in other current assets for fiscal 2023 was -$164.88K.
- NEXENTIS TECHNOLOGIES INC. increase (decrease) in other current assets for fiscal 2022 was -$39.89K, a 119.88% decline from fiscal 2021.
- NEXENTIS TECHNOLOGIES INC. increase (decrease) in other current assets for fiscal 2021 was $200.67K, a 321.80% increase from fiscal 2020.
- NEXENTIS TECHNOLOGIES INC. increase (decrease) in other current assets for fiscal 2020 was $47.58K.
| Period end | Increase (Decrease) in Other Current Assets 3 month | Increase (Decrease) in Other Current Assets 6 month | Increase (Decrease) in Other Current Assets 9 month | Increase (Decrease) in Other Current Assets 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$41.94K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$103.16K derived: sum of 2 quarters · filed 2024-04-01 | -$180.86K derived: sum of 3 quarters · filed 2024-04-01 | -$164.88K 10-K · filed 2024-04-01 |
| 2023-09-30 | -$61.21K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$138.91K derived: sum of 2 quarters · filed 2023-11-14 | -$122.94K 10-Q · filed 2023-11-14 | -$404.39K derived: sum of 4 quarters · filed 2024-04-01 |
| 2023-06-30 | -$77.70K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$61.73K 10-Q · filed 2023-08-14 | -$343.18K derived: sum of 3 quarters · filed 2024-04-01 | -$310.31K derived: sum of 4 quarters · filed 2024-04-01 |
| 2023-03-31 | $15.98K 10-Q · filed 2023-05-15 | -$265.48K derived: sum of 2 quarters · filed 2024-04-01 | -$232.60K derived: sum of 3 quarters · filed 2024-04-01 | $23.95K derived: sum of 4 quarters · filed 2024-04-01 |
| 2022-12-31 | -$281.45K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$248.58K derived: sum of 2 quarters · filed 2024-04-01 | $7.97K derived: sum of 3 quarters · filed 2024-04-01 | -$39.89K 10-K · filed 2024-04-01 |
| 2022-09-30 | $32.87K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $289.43K derived: sum of 2 quarters · filed 2023-11-14 | $241.57K 10-Q · filed 2023-11-14 | -$158.70K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $256.56K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $208.69K 10-Q · filed 2023-08-14 | -$191.57K derived: sum of 3 quarters · filed 2023-08-14 | -$271.31K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$47.86K 10-Q · filed 2023-05-15 | -$448.13K derived: sum of 2 quarters · filed 2023-05-15 | -$527.87K derived: sum of 3 quarters · filed 2023-05-15 | $147.64K derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$400.27K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | -$480.01K derived: sum of 2 quarters · filed 2023-03-27 | $195.51K derived: sum of 3 quarters · filed 2023-03-27 | $200.67K 10-K · filed 2023-03-27 |
| 2021-09-30 | -$79.74K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $595.77K derived: sum of 2 quarters · filed 2022-11-14 | $600.94K 10-Q · filed 2022-11-14 | $632.42K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $675.51K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $680.68K 10-Q · filed 2022-08-15 | $712.16K derived: sum of 3 quarters · filed 2022-08-15 | $697.74K derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $5.17K 10-Q · filed 2022-05-16 | $36.65K derived: sum of 2 quarters · filed 2022-05-16 | $22.23K derived: sum of 3 quarters · filed 2022-05-16 | $41.88K derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | $31.48K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $17.06K derived: sum of 2 quarters · filed 2022-03-31 | $36.72K derived: sum of 3 quarters · filed 2022-03-31 | $47.58K 10-K · filed 2022-03-31 |
| 2020-09-30 | -$14.42K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $5.24K derived: sum of 2 quarters · filed 2021-11-15 | $16.09K 10-Q · filed 2021-11-15 | -$25.43K derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $19.66K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $30.52K 10-Q · filed 2021-08-16 | -$11.01K derived: sum of 3 quarters · filed 2021-08-16 | -$19.01K derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | $10.86K 10-Q · filed 2021-05-18 | -$30.67K derived: sum of 2 quarters · filed 2021-05-18 | -$38.67K derived: sum of 3 quarters · filed 2021-05-18 | -$59.26K derived: sum of 4 quarters · filed 2021-05-18 |
| 2019-12-31 | -$41.53K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | -$49.53K derived: sum of 2 quarters · filed 2021-03-29 | -$70.12K derived: sum of 3 quarters · filed 2021-03-29 | -$49.74K 10-K · filed 2021-03-29 |
| 2019-09-30 | -$8.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$28.59K derived: sum of 2 quarters · filed 2020-11-12 | -$8.21K 10-Q · filed 2020-11-12 | |
| 2019-06-30 | -$20.59K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | -$211.00 10-Q · filed 2020-08-11 | ||
| 2019-03-31 | $20.38K 10-Q · filed 2020-05-15 | |||
| 2018-12-31 | -$27.12K 10-K · filed 2020-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |